Antibiotic crisis needs united global response, say UK experts

12 May 2014

Growing resistance to antibiotics and other drugs demands a coordinated global response on the same scale as efforts to address climate change, experts say. Without an international commitment to tackle the issue, the world faces a future in which simple infections that have been treatable for decades become deadly diseases, they warn.

Resistance to antibiotics to tackle bacterial infections and antimicrobial drugs used to treat parasites, viruses and fungi is spreading at an alarming rate. Treatment for many infectious diseases is now reliant on just one or two drugs.

Mark Woolhouse, of the University of Edinburgh, Scotland, Centre for Immunity, Infection and Evolution, and Jeremy Farrar, director of the UK-based Wellcome Trust, a global charitable foundation spending £750 million ($1.26 billion) annually on biomedical research, outlined their concerns at an event hosted by the Royal Society in London and in a Comment piece published on-line in the journal Nature on Thursday (May 22).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical